ArticleBMC cancer2025
Overexpression of KRAS enhanced the stemness of esophageal cancer cells inhibited by overexpression of circ0043898.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOur previous study revealed that circ0043898 is downregulated in esophageal cancer (EC), and its overexpression attenuates the progression of EC. The objective of this article is to explore whether circ0043898 inhibits tumor progression by inhibiting cancer stem cells (CSCs) in EC.
methodsPCDH-circ0043898 plasmid was transfected into EC cells, and the effect of overexpression was verified by qRT-PCR. Immunofluorescence, flow cytometry, and stem cell spheroidization were used to detect CSCs phenotype changes. RNA sequencing was adopted to identify downstream regulatory genes and p-PI3K, PI3K, and KRAS expressions were validated by western blot. To investigate whether KRAS functions downstream of circ0043898 in regulating cancer stemness, we co-transfected EC cells with both KRAS and circ0043898 plasmids and examined CSCs phenotypes.
resultscirc0043898 was overexpressed in the EC cells, and reduced stem cell markers (CD44 and CD133) and the number of stem cell spheroidization. In addition, overexpression of circ0043898 changed many genes expression, including reduced p-PI3K, PI3K, and KRAS expressions. Moreover, overexpression of KRAS attenuated the effect of overexpressed circ0043898 on CSCs phenotype.
conclusionsOverexpression of circ0043898 reduced CSCs markers and the number of stem cell spheroidization. However, the overexpression of KRAS attenuated the inhibition effect of overexpressed circ0043898 on CSCs marker and the number of stem cell spheroidization. These findings identify a potential therapeutic target for the EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.